Journal
CANCER
Volume 119, Issue 12, Pages 2230-2238Publisher
WILEY-BLACKWELL
DOI: 10.1002/cncr.28049
Keywords
cisplatin; clinical trial; concurrent-adjuvant chemotherapy; fluorouracil; nasopharyngeal carcinoma
Categories
Funding
- Science Foundation of Key Hospital Clinical Program of Ministry of Health of the People's Republic of China [2010-178]
- Key Scientific and Technological Innovation Program for Universities of Guangdong Province [cxzd1005]
- Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme
Ask authors/readers for more resources
BACKGROUND The objective of this study was to evaluate the long-term survival and late toxicities of concurrent-adjuvant chemotherapy in patients with stage III through IVB nasopharyngeal carcinoma (NPC) from endemic regions of China. METHODS Patients with stage III to IVB NPC were assigned randomly to receive radiotherapy (RT) alone (the RT group) or RT plus concurrent adjuvant chemotherapy (the CRT group). CRT patients received concurrent cisplatin (40 mg/m2) weekly during RT followed by cisplatin (80 mg/m2) and fluorouracil (800 mg/m2 daily for 5 days) every 4 weeks for 3 cycles. The primary endpoint was overall survival. RESULTS In total, 316 patients underwent randomization, with 158 to each group. At a median follow-up of 70 months, the 5-year overall survival rate was 72% for the CRT group and 62% for the RT group (hazard ratio, 0.69; 95% confidence interval, 0.48-0.99; P=.043). Failure-free survival was significantly higher in the CRT group (P=.020). Most late toxicities were similar (33% vs 26%; P=.089), except for cranial neuropathy (P=.042), peripheral neuropathy (P=.041), and ear damage (P=.048), which were significantly increased in the CRT group. CONCLUSIONS The addition of concurrent adjuvant chemotherapy to RT provides survival benefits to patients with stage III through IVB NPC in endemic regions of China, and it does not increase most late toxicities apart from cranial neuropathy, peripheral neuropathy, and ear damage. Cancer 2013;119:2230-2238. (c) 2013 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available